Results 21 to 30 of about 8,113 (209)

Bosentan therapy for portopulmonary hypertension [PDF]

European Respiratory Journal, 2005
The dual endothelin receptor antagonist bosentan has been approved in several countries for pulmonary arterial hypertension, and patients with portopulmonary hypertension (PPHTN) have not specifically been excluded. However, no data have been published on the efficacy and safety of bosentan in this patient population.
Joachim Schauer, C Marx, Michael Halank, Hans-Jürgen Seyfarth, Marius M. Hoeper, Gert Hoeffken, Jost Niedermeyer, Jörg Winkler   +7 more
openaire   +2 more sources

Spectroscopic analysis of bosentan in biological samples after a liquid-liquid microextraction [PDF]

BioImpacts, 2015
Introduction: Microextraction processes with UV-Vis measurement have been developed and validated for analysis of bosentan in biological samples. Methods: In this work, liquid–liquid microextraction procedures (DLLME & USAEME) were employed for cleanup ...
Sanaz Sajedi-Amin, Karim Assadpour-Zeynali, Vahid Panahi-Azar, Abbas Kebriaeezadeh, Maryam Khoubnasabjafari, Khlalil Ansarin, Vahid Jouyban-Gharamaleki, Abolghasem Jouyban   +7 more
doaj   +1 more source

Potential benefit of bosentan therapy in borderline or less severe pulmonary hypertension secondary to idiopathic pulmonary fibrosis—an interim analysis of results from a prospective, single-center, randomized, parallel-group study

BMC Pulmonary Medicine, 2017
Background No drugs have been approved for the treatment of patients with pulmonary hypertension (PH) secondary to idiopathic pulmonary fibrosis (IPF), particularly those with idiopathic honeycomb lung.
Yosuke Tanaka, Mitsunori Hino, Akihiko Gemma   +2 more
doaj   +1 more source

A Bayesian network meta-analysis on the efficacy and safety of eighteen targeted drugs or drug combinations for pulmonary arterial hypertension

Drug Delivery, 2018
Pulmonary arterial hypertension (PAH) can be relieved by pharmacological interventions, especially the targeted drug, which is classified into endothelin receptor antagonist, phosphodiesterase 5 inhibitor, prostaglandin I2, soluble guanylate cyclase ...
Sumei Wang, Miao Yu, Xiangchun Zheng, Shangjuan Dong   +3 more
doaj   +1 more source

Sildenafil and bosentan plasma concentrations in a human immunodeficiency virus-infected patient with pulmonary arterial hypertension treated with ritonavir-boosted protease inhibitor

Infectious Disease Reports, 2015
Sildenafil and bosentan are increasingly used for the treatment of pulmonary arterial hypertension (PAH) in HIV-infected patients. However, concerns exist about pharmacokinetic interactions among sildenafil, bosentan and antiretroviral drugs, including ...
Pierangelo Chinello, Stefania Cicalini, Simona Pichini, Roberta Pacifici, Massimo Tempestilli, Maria P. Cicini, Leopoldo P. Pucillo, Nicola Petrosillo   +7 more
doaj   +1 more source

Slow receptor dissociation kinetics differentiate macitentan from other endothelin receptor antagonists in pulmonary arterial smooth muscle cells. [PDF]

PLoS ONE, 2012
Two endothelin receptor antagonists (ERAs), bosentan and ambrisentan, are currently approved for the treatment of pulmonary arterial hypertension (PAH), a devastating disease involving an activated endothelin system and aberrant contraction and ...
John Gatfield, Celia Mueller Grandjean, Thomas Sasse, Martine Clozel, Oliver Nayler   +4 more
doaj   +1 more source

Iontophoresis of endothelin receptor antagonists in rats and men. [PDF]

PLoS ONE, 2012
The treatment of scleroderma-related digital ulcers is challenging. The oral endothelin receptor antagonist (ERA) bosentan has been approved but it may induce liver toxicity.
Matthieu Roustit, Sophie Blaise, Claire Arnaud, Marcin Hellmann, Claire Millet, Diane Godin-Ribuot, Boris Dufournet, Jean Boutonnat, Christophe Ribuot, Jean-Luc Cracowski   +9 more
doaj   +1 more source

Chronic dosing with metformin plus bosentan decreases in vitro pulmonary artery contraction from isolated arteries in adults with pulmonary hypertension [PDF]

Journal of Cardiovascular and Thoracic Research, 2019
Introduction: Pulmonary arterial hypertension (PAH) specific drug therapy using bosentan has significantly improved quality of life and survival, although PAH is still an incurable disease.
Shutan Liao, Dongsheng Li, Zheng Hui, Craig S McLachlan, Yang Zhang   +4 more
doaj   +1 more source

Resolution of Severe PAH After Late VSD Closure in an 8-Year-Old: Clinical Prudence or Adventurism? [PDF]

Pulm Circ
Pulmonary Circulation, Volume 15, Issue 2, April 2025.
Gupta SK, Kothari SS.
europepmc   +2 more sources

Treatment of patients with Eisenmenger's syndrome with Bosentan [PDF]

Cardiology in the Young, 2007
We treated prospectively 14 patients with Eisenmenger's syndrome, with a mean age of 10 years, ranging from 3 to 18 years. Treatment continued for 12 months, and demonstrated a lasting symptomatic improvement, but no improvement in terms of mean saturation of oxygen over 24 hours.
Henrik Holmstrøm, Per Morten Fredriksen, Henrik Brun, Erik Thaulow   +3 more
openaire   +3 more sources